Abstract P4-21-39: Neo-adjuvant treatment with trastuzumab and pertuzumab associated with palbociclib and fulvestrant in HER2-positive and ER-positive breast cancer: Effect on Ki67 during and after treatment. A phase II Michelangelo studyLorenzo Gianni, G. Viale, Claudio Zamagni et al.|Cancer Research|2017Cited by 5
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapiesMaurizio Callari, Giampaolo Bianchini, Matteo Dugo et al.|Nature Communications|2025Cited by 5